Image 01
George C. Prendergast, PhD, editor-in-chief of Cancer Research, interacts with attendees during his Meet the Editor session at the AACR Annual Meeting 2017. During his term as editor-in-chief, Dr. Prendergast expanded the focus of Cancer Research to reflect the dramatic changes in cancer science.


Keith T. Flaherty, MD, outlines his vision for Clinical Cancer Research during his Meet the Editor session at the AACR Annual Meeting 2017. Dr. Flaherty began his term as the new editor-in-chief of CCR in January 2017.

In 1916, the AACR launched The Journal of Cancer Research, the first cancer journal published in English. This first AACR publication was renamed in 1931 as The American Journal of Cancer, which was the organization’s official journal for ten years. In 1941, the AACR relaunched the journal as Cancer Research, which has remained in continuous publication to this day.

In the 76 years since its launch, Cancer Research has become one of the most frequently cited cancer journals in the world, and the AACR’s scientific publishing program has expanded to eight journals to cover the full spectrum of basic, translational, clinical, and epidemiological research. With the guidance of their editorial boards and the leadership from their editors-in-chief, AACR journals serve the organization’s mission by providing forums for the most innovative cancer science.

New Editorial Leadership for Clinical Cancer Research

In January 2017, the AACR appointed Keith T. Flaherty, MD, as the new editor-in-chief of Clinical Cancer Research, the journal of clinical and translational cancer research that has provided a critical bridge between the laboratory and the clinic for more than twenty years. A world-renowned physician-scientist, Flaherty pioneered the development of targeted therapies matched to the genetic characteristics of a patient’s tumor and led clinical trials to evaluate some of these therapies. He assumed the editor-in-chief position of Clinical Cancer Research after six years as a senior editor of the journal’s melanoma section, and his considerable expertise will inform his leadership of the journal in its third decade of publication.


The AACR recognizes the achievements of George C. Prendergast, PhD, whose term of service as editor-in-chief of Cancer Research ended in 2017. His dedication and leadership have benefited the AACR publishing program as well as the cancer research community:

As the most comprehensive journal in the AACR’s scientific publishing program, Cancer Research represents the entire field of cancer science, publishing articles of broad interest and high impact in basic, translational, and clinical research. However, the field has changed rapidly over the past eight years; during his term as editor-in-chief, Dr. Prendergast had the vision to recognize these changes and expand the journal’s focus to highlight them. Under his editorial leadership, Cancer Research integrated cancer science with peripheral fields such as physics and re-emerging fields like immunology—inspiring investigators to take new approaches to the cancer problem and making the journal as dynamic as the areas it covers.

Under Dr. Prendergast’s leadership, Cancer Research achieved its highest-ever Impact Factor ranking (JCR; Clarivate Analytics, 2017) and continued to be one of the most frequently cited cancer journals in the world. He achieved this ranking by attracting and publishing high-impact studies; the three most-cited articles in the journal during his tenure are listed below:

    • Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
      [Rahib et al., June 2014]
    • Long Noncoding RNA HOTAIR Regulates Polycomb-Dependent Chromatin Modification and Is Associated with Poor Prognosis in Colorectal Cancers
      [Kogo et al., October 2011]
    • Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
      [Gutschner et al., February 2013]

aacr journal
launch dates


The Journal of Cancer Research
(Inaugural Editor: Richard P. Weil)


The American Journal of Cancer
(Inaugural Editor: Francis Carter Wood)


Cancer Research
(Inaugural Editor: James B. Murphy)


Cell Growth & Differentiation
(Inaugural Editor: George F. Vande Woude, PhD, FAACR)


Cancer Epidemiology, Biomarkers & Prevention
(Inaugural Editor: Pelayo Correa, MD)


Clinical Cancer Research
(Inaugural Editor: John Mendelsohn, MD, FAACR)


Molecular Cancer Therapeutics
(Inaugural Editor: Daniel D. Von Hoff, MD, FAACR)


Molecular Cancer Research
(Inaugural Editor: Michael B. Kastan, MD, PhD, FAACR; formerly Cell Growth & Differentiation)


Cancer Prevention Research
(Inaugural Editor: Scott Lippman, MD)


Cancer Discovery
(Inaugural Editors: Lewis C. Cantley, PhD, FAACR, and José Baselga, MD, PhD, FAACR)


Cancer Immunology Research
(Inaugural Editor: Glenn Dranoff, MD)


At the AACR Journals Reception during the Annual Meeting, AACR Publications Committee chair Victor Velculescu, MD, PhD (fifth from left) acknowledges the authors of the most-cited papers published in AACR journals in 2015.


Of citations in the Oncology category were garnered by AACR journals, according to the 2016 Journal Citation Report® (Clarivate Analytics, 2017). The eight AACR journals represent 3.7% of the 217 journals in the category.


AACR journals ranked in the top 10% in the Oncology category with regard to Impact Factor, according to the Journal Citation Report released in July 2017. Cancer Discovery ranked 7th out of all oncology journals, followed by Clinical Cancer Research (12th), Cancer Research (15th), and Cancer Immunology Research (17th).


Citations to AACR journals were made in 2016, according to the Journal Citation Report released in July 2017.

26 million

Full-text views of AACR journal articles were recorded in 2017.


Robert D. Schreiber, PhD (left), and Philip D. Greenberg, MD (right), co-editors of Cancer Immunology Research, discuss the journal at their Meet the Editors session during the AACR Annual Meeting.

The AACR thanks its editors-in-chief for their hard work and stewardship of its scientific publishing program.

Cancer Discovery

Lewis C. Cantley, PhD, FAACR

Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College
New York, New York

José Baselga, MD, PhD, FAACR

Memorial Sloan Kettering Cancer Center
New York, New York

Cancer Epidemiology, Biomarkers & Prevention

Timothy R. Rebbeck, PhD

Dana-Farber Cancer Institute
Boston, Massachusetts

Cancer Immunology Research

Robert D. Schreiber, PhD

Washington University School of Medicine
St. Louis, Missouri

Philip D. Greenberg, MD

Fred Hutchinson Cancer Research Center
Seattle, Washington

Cancer Prevention Research

Scott M. Lippman, MD

UC San Diego Moores Cancer Center
San Diego, California

Cancer Research

George C. Prendergast, PhD

Lankenau Institute for Medical Research
Wynnewood, Pennsylvania

Clinical Cancer Research

Keith T. Flaherty, MD

Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Molecular Cancer Research

Karen E. Knudsen, PhD

Kimmel Cancer Center
Philadelphia, Pennsylvania

Molecular Cancer Therapeutics

Napoleone Ferrara, MD, FAACR

UC San Diego Moores Cancer Center
San Diego, California